Immunotherapy + Targeted Therapy for Genitourinary Cancers
Trial Summary
The trial does not specify if you need to stop taking your current medications, but it does mention that you cannot take certain medications like warfarin and strong CYP3A4 inducers or inhibitors. It's best to discuss your current medications with the trial team to see if any adjustments are needed.
Research shows that combining Cabozantinib and Nivolumab, with or without Ipilimumab, has been effective in treating advanced genitourinary cancers, including urothelial carcinoma. These drugs work by boosting the immune system to fight cancer, and they have shown promising results in improving patient outcomes.
12345Research shows that the combination of cabozantinib, nivolumab, and ipilimumab has been studied for safety in various cancers, including genitourinary tumors and renal cell carcinoma. While specific safety details are not provided, these studies indicate that the treatment has been evaluated for safety in humans.
16789This drug combination is unique because it combines targeted therapy (Cabozantinib) with immunotherapy (Nivolumab and Ipilimumab), aiming to enhance the immune system's ability to fight cancer while also targeting specific cancer cell pathways. This approach is being explored for its potential to improve outcomes in genitourinary cancers, where traditional immunotherapy alone has shown limited success.
14101112Eligibility Criteria
This trial is for adults with rare genitourinary tumors that have spread, who can swallow pills and don't have active brain metastases or certain illnesses. They may have had up to two cancer treatments before or none at all. Participants must not be on warfarin, have a good performance status (Karnofsky >=80%), no recent major surgeries, no severe allergies to monoclonal antibodies, and controlled medical conditions are okay.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Advanced renal cell carcinoma (RCC)
- Hepatocellular carcinoma (HCC)
- Locally advanced or metastatic differentiated thyroid cancer (DTC)
- Medullary thyroid cancer
- Advanced renal cell carcinoma (RCC)
- Hepatocellular carcinoma (HCC)
- Locally advanced or metastatic differentiated thyroid cancer (DTC)